Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

116.48 -1.53 (-1.30%)
Streaming Delayed Price Updated: 11:25 AM EDT, Oct 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,258,899
Open 116.68
Bid (Size) 116.48 (1)
Ask (Size) 116.49 (1)
Prev. Close 118.01
Today's Range 115.79 - 116.79
52wk Range 86.96 - 148.15
Shares Outstanding N/A
Dividend Yield 1.52%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Eli Lilly Commits $4.5B To New Facility, Banking On Mounjaro, Zepbound's Weight Loss Success Despite Short-Term Stock Challenges
Eli Lilly (NYSE:LLY) investing $4.5B to create Lilly Med Foundry, with goal of faster drug pipeline and scaling molecules to medicines. Stock outlook mixed. 
Via Benzinga
Eli Lilly Invests $4.5B In New Medicine Foundry for Advanced Drug Manufacturing To Push US Pharma Boundaries
Eli Lilly announces a $4.5B investment to build the Lilly Medicine Foundry, a state-of-the-art facility in Indiana. The new center will focus on advanced drug development and manufacturing, reinforcing... 
Via Benzinga

Performance

YTD
+14.07%
+14.07%
1 Month
-14.52%
-14.52%
3 Month
-18.53%
-18.53%
6 Month
-7.89%
-7.89%
1 Year
+26.88%
+26.88%

More News

Read More
Eli Lilly Nears First Trillion Pharma Title, But Investors Caution Amid Sky-High Valuation
Via Benzinga
US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could be Next
Via Benzinga
Topics Economy
Exposures Interest Rates
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $4,700 Today
Via Benzinga
Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition
Via Investor Brand Network
Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition
Via FinancialNewsMedia
Roche Fast-Tracks Obesity Drug Development, Eyes Over $3B Sales Potential
Via Benzinga
Investors should take note of NYSE:NVO, a growth stock that remains attractively priced.
Via Chartmill
'Stop Ripping Us Off' – Incredibly, Elon Musk And Bernie Sanders Seem To Agree On This One Thing – 'I Really Am With Bernie On This One'
Via Benzinga
Success in This New Battleground Could Make Eli Lilly and Novo Nordisk Stock Absolutely Fly for Years
Via The Motley Fool
Benzinga Bulls And Bears: Apple, Tesla, Novo Nordisk, Bitcoin — And Shiba Inu's Major Stablecoin Tease
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Latest Inflation Data Cements Fed's Interest Rate Call, S&P 500 Hits All-Time High, Biden Adviser Backs China EV Ban At Detroit Economic Club: This Week In The Markets
Via Benzinga
Topics Artificial Intelligence Economy Stocks
Exposures Artificial Intelligence Interest Rates US Equities
Novo Nordisk Slips On Analyst Warning Of Weaker Wegovy Sales
Via Investor's Business Daily
Cassava Sciences, enVVeno Medical And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
Novo Nordisk Just Committed More Than $1.1 Billion to Make the Next Ozempic, but Is the Stock a Buy?
Via The Motley Fool
Novo Nordisk And Evotec Collaborate On Stem Cell-Based Therapy Development
Via Benzinga
Forget Novo Nordisk, Buy This Magnificent Dividend Stock Instead
Via The Motley Fool
EXCLUSIVE: Vivani Medical Advances Its Obesity Treatment Implant With New Clinical Trial in Australia
Via Benzinga
Novo Nordisk's $600 Million Gambit Could Be a Game Changer for the Stock. Here's Why.
Via The Motley Fool
Lose Weight With Novo Nordisk Drugs, Gain Money With Stock
Via Benzinga
Popular Ozempic May Have New Use As Semaglutide Drugs Linked To Reduced Overdose Risk In Diabetic Opioid Users
Via Benzinga
Can Novo Nordisk's Weight Loss Drug Ozempic Help Stem The Devastating Addiction Crisis? New Research Says Yes
Via Benzinga
Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly Diagnosed Myeloma Patients, Speeds Path To Profitability
Via Benzinga
Exposures Product Safety
EXCLUSIVE: Novo Nordisk Faces Political Heat Over Weight-Loss Drug Prices Ahead Of Elections, Yet 'The Real Issue Is With The Middlemen'
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.